Evidence map›Paper›PMID 28762374›Full record

ArticleProstate cancer and prostatic diseases2017

Molecular alterations in prostate cancer and association with MRI features.

D Lee, J Fontugne, N Gumpeni, K Park, T Y MacDonald, B D Robinson, A Sboner, M A Rubin, J M Mosquera, C E Barbieri

Abstract read
PubMed Publisher
In one paragraph

Article in Prostate cancer and prostatic diseases, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. SPOP and cancer: a systematic review.American journal of cancer research · 2020
    Review
  7. Article
  8. Article
  9. SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity.Clinical cancer research : an official journal of the American Association for Cancer Research · 2018
    Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

D LeeDepartment of Urology, Weill Cornell Medicine and New York-Presbyterian, New York, NY, USA.
J FontugneDepartment of Pathology and Laboratory Medicine, Weill Cornell Medicine and New York-Presbyterian, New York, NY, USA.
N GumpeniDepartment of Radiology, Weill Cornell Medicine and New York-Presbyterian, New York, NY, USA.
K ParkDepartment of Pathology and Laboratory Medicine, Weill Cornell Medicine and New York-Presbyterian, New York, NY, USA.
T Y MacDonaldDepartment of Pathology and Laboratory Medicine, Weill Cornell Medicine and New York-Presbyterian, New York, NY, USA.
B D RobinsonDepartment of Urology, Weill Cornell Medicine and New York-Presbyterian, New York, NY, USA.
A SbonerDepartment of Urology, Weill Cornell Medicine and New York-Presbyterian, New York, NY, USA.
M A RubinDepartment of Urology, Weill Cornell Medicine and New York-Presbyterian, New York, NY, USA.
J M MosqueraDepartment of Urology, Weill Cornell Medicine and New York-Presbyterian, New York, NY, USA.
C E BarbieriDepartment of Urology, Weill Cornell Medicine and New York-Presbyterian, New York, NY, USA.

Funding

Epitomic Biomarkers of Prostate CancerU01CA111275 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CHINNAIYAN, ARUL M, RUBIN, MARK A. · 2004 to 2015
$6.8M
Towards Understanding Prostate Cancer HeterogeneityR01CA125612 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI RUBIN, MARK A. · 2007 to 2017
$3.4M
Genomic instability and DNA repair in a distinct molecular class of prostate cancK08CA187417 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI BARBIERI, CHRISTOPHER E · 2014 to 2018
$865k
NCI NIH HHS K08 CA187417NCI NIH HHS R01 CA125612NCI NIH HHS U01 CA111275
6 · The paper itself

Abstract

backgroundMultiparametric magnetic resonance imaging (mpMRI) has been increasingly used for prostate cancer (PCa). Recent studies identified distinct molecular subclasses of PCa with recurrent genomic alterations. However, the associations between molecular alterations in PCa and characteristics on mpMRI are unknown. Therefore, the objective of this study was to investigate recurrent molecular alterations in PCa and their associations with mpMRI features.

methodsSixty-two PCa nodules >0.5 cm had a preoperative mpMRI. Nodules were evaluated for ERG rearrangement, PTEN deletion, SPINK1 overexpression, SPOP mutation and CHD1 deletion. Each PCa focus was matched to the corresponding location on mpMRI. Lesions were scored by single observer according to the PI-RADSv2 scale.

resultsOf the 62 nodules, 22 (35.5%) were ERG positive, 6 (9.7%) had SPINK1 overexpression, 6 (9.7%) had SPOP mutations, 4 (6.5%) had CHD1 deletions and 1 (1.6%) had PTEN deletion. All of the nodules with CHD1 deletions were not visible on mpMRI (P=0.037). All of the nodules with SPINK1 overexpression were visible on mpMRI, although the association was not statistically significant (P=0.06). There were no significant associations between any molecular alteration with the severity of the PI-RADS scores (all P>0.05).

conclusionsThis investigation represents the first description of an association between recurrent molecular alterations and the characterization of PCa nodules on mpMRI. This study can be considered hypothesis-generating for future studies to rigorously evaluate the association of specific PCa molecular subclasses with imaging features and potentially define specific subsets of PCa for which the utility of MRI is higher or lower.

Indexed as

Magnetic Resonance ImagingAgedDNA-Binding ProteinsDNA HelicasesGene Expression Regulation, NeoplasticHumansMaleMiddle AgedMutationNuclear ProteinsProstateProstatic NeoplasmsPTEN PhosphohydrolaseRepressor ProteinsTranscriptional Regulator ERGTrypsin Inhibitor, Kazal PancreaticCHD1 protein, humanDNA-Binding ProteinsDNA HelicasesERG protein, humanNuclear ProteinsPTEN PhosphohydrolasePTEN protein, humanRepressor ProteinsSPINK1 protein, humanSPOP protein, humanTranscriptional Regulator ERGTrypsin Inhibitor, Kazal Pancreatic

Identifiers

PMID28762374

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.